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Abstract
Rational An increasing number of fatal road-accidents have
been reported in which ecstasy was found in the blood of
drivers. Although, ecstasy is frequently found to have been
used in combination with alcohol, studies on the acute
effects of ecstasy co-administered with alcohol on driving
performance are relatively rare.
Objective The present study was designed to establish the
extent of driver impairment as a consequence of ecstasy or
combined ecstasy and alcohol use as compared to driving
under the influence of 0.3‰, 0.5‰ and 0.8‰ alcohol.
Furthermore, subjective performance was also assessed.
Results Alcohol and ecstasy mainly influenced automated
driving performance such as lateral and speed control.
However, small to no effects of the substances were found
on more complex driving behaviour. Overall, variance within
the different driving measures was high especially when
participants were treated with 3.4-methylenedioxy-metham-
phetamine (MDMA) and alcohol. Furthermore, equivalence
testing showed that combined use may lead to impaired
driving for some, but not all, drivers. Participants rated their
own performance to be slightly worse than normal in both
studies. Since driving was actually seriously deteriorated, this
was a falsely positive assessment of their condition.
Conclusions The dissociation between subjective percep-
tions and objective performance decrements are important
notions for traffic safety since this may affect a driver’s
judgement of whether or not it is safe to drive. For example,
an intoxicated individual might decide to drive because the
feelings of alertness caused by MDMA cloud the impairing
effects of other drugs such as alcohol, thereby creating a
potentially serious risk for traffic safety.
Keywords Driving simulator . Driving performance .
Alcohol . Ecstasy
Introduction
Driving under the influence of drugs is an important public
health and road traffic safety related problem (Christophersen
and Morland 1997; Drummer et al. 2003; Movig et al. 2004;
Mura et al. 2006; Ojaniemi et al. 2009; Schwilke et al.
2006). Several fatal and non-fatal injurious road accidents
have been reported in which ecstasy was found in the blood
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of drivers (Henry 1992; Verschraagen et al. 2007). This is
not surprising considering that ecstasy is the second most
popular drug in Europe after cannabis (EMCDDA 2010). In
fact, the EMCDDA estimates that the life time prevalence
(ever used) of ecstasy use for adults (16–64 years) in Europe
ranges between 0.3% and 9.6% with current ecstasy use
(used last year) estimated to range between 0.1% and 3.7%.
Ecstasy refers to a synthetic substance that is
chemically related to amphetamines but differs to some
extent in its effects. Whereas amphetamines are mainly
known for their energising effects, ecstasy is commonly
appreciated for its entactogenic properties. Concretely
this means that besides increased feelings of energy
after the ingestion of ecstasy, there is also a feeling of
euphoria and an intensification of impressions in contact
with other people, music and light (Baylen and
Rosenberg 2006). The best-known member of the ecstasy
group of drugs is 3.4-methylenedioxy-methamphetamine
(MDMA), but other analogues are also sometimes found
in ecstasy tablets (3,4-Methylenedioxyamphetamine
(MDA), MDEA). The drug is commonly used in social
scenes such as dance events and is frequently combined
with other drugs such as cannabis and amphetamines and
(most frequently) alcohol (Brookhuis et al. 2004; Nabben
et al. 2007; Mora et al. 2009).
Only, a small number of experimental studies have
assessed the acute effects of MDMA on skills related to
driving. These studies generally showed that MDMA acted as
a psychomotor stimulant that increases arousal and psycho-
motor function. As such, it was demonstrated that MDMA
improved tracking performance (Lamers et al. 2003), psycho-
motor speed (Dumont et al. 2008, 2010; Lamers et al. 2003)
and impulse control (Ramaekers and Kuypers 2006).
However, MDMA has also been shown to have a negative
effect on skills that are important for driving, for example the
impairment of spatial memory performance (Kuypers and
Ramaekers 2005; Kuypers et al. 2006, 2007), movement
perception (Kuypers and Ramaekers 2005; Ramaekers et al.
2009) and divided attention (Lamers et al. 2003; Kuypers et
al. 2007). Furthermore, when combined with alcohol,
MDMA’s stimulant effects are generally not strong enough
to fully overcome alcohol-induced impairment of psycho-
motor function (Dumont et al. 2008, 2010; Hernandez-Lopez
et al. 2002)
Reports on the acute effects of MDMA co-administered
with alcohol on driving performance are also relatively rare
(Brookhuis et al. 2004; Kuypers et al. 2006). Kuypers et al.
(2006) assessed the influence of 75 and 100 mg MDMA
alone and combined with alcohol (average BAC around
0.4‰) on actual driving performance in a within-subjects
design. They found that automated driving performance, as
measured with the road tracking test (O’Hanlon et al.
1982), was impaired by alcohol (i.e. increased standard
deviation of the lateral position; SDLP) but decreased after
use of MDMA (both dosages). Moreover, the standard
deviation of speed (SDSP) also decreased under the
influence of MDMA (both dosages) although it was
unaffected by alcohol. Co-administration of 100 mg but
not 75 mg MDMAwas also found to moderate the alcohol-
induced impairment in SDLP. Furthermore, there was no
effect of co-administration on SDSP. The responses of
drivers to speed changes of a lead vehicle as measured by
the car following test (Brookhuis et al. 1994) were
unaffected by MDMA (both dosages) alone or when co-
administered with alcohol. However, because of the
obvious reason that high-risk situations in an experiment
on the road cannot be (ethically) acceptable, other more
complex interactions with traffic participants and risk
taking in traffic could not be investigated in this study.
Brookhuis et al. (2004) on the other hand used a driving
simulator to test MDMA effects and could therefore safely
assess the more high-risk aspects of driving.
In this latter study, recreational ecstasy users who were
going to a dance party drove in the simulator before going
to the party, 1 hour after the use of their own, self-bought
and self-administered ecstasy (average MDMA, 59 mg).
After the party, they were tested again while they were
under the influence of MDMA and various other substances
such as (in 80% of the cases) marihuana and (in 90% of the
cases) alcohol (an average BAC of 0.39‰ once back in the
lab approximately 1 h after the party). The participants were
also tested in a sober condition on a different day at a
comparable time. The results indicated that SDLP was
unaffected by MDMA alone but was impaired by multidrug
use. From non drug to MDMA and from MDMA to multi
drug both speed and SDSP increased. As found in the on-
road study, performance on the car following test was
unaffected in both drug conditions. However, measures of
risk taking and situation awareness in complex traffic
situations were affected by multidrug use (increased gap
time and an increased number of crashes). Because of the
quasi-experimental design, i.e. no control over the active
substances, however, it is hard to draw straightforward
conclusions from this experiment on the influence of
combined alcohol and MDMA use on critical aspects of
driving performance.
Therefore, the aim of the present study was to investigate
the risks involved in driving under the influence of MDMA
(100 mg) alone and when co-administered with alcohol
(0.5‰) in a controlled environment, i.e. in driving
simulator, with in controlled design. What is more to
determine the implications of the results for traffic safety?
To this end a double blind ‘alcohol reference’ study was
initially performed. In this study (study 1) the influence of
three levels of alcohol (0.3‰, 0.5‰ and 0.8‰) were tested
against a placebo condition on a set of measures within
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specifically developed scenarios, similar to the ones later
used in the study on MDMA and driving (study 2).
According to Dumont et al. (2010), MDMA may
provide a sense of adequate performance that is not in
accordance with actual performance. This is an important
notion for traffic safety and therefore subjective effects are
also assessed.
Study 1: alcohol reference study
Methods and materials
Participants
Nineteen participants started the study; however, two
dropped out during the experiment due to physical
problems not related to the experiment. Therefore, data of
17 participants (nine males, eight females) with an average
age of 23.6 (SD=3.8) years were analysed. The participants
were all experienced drivers who had held their driving
licence for at least 3 years (mean (SD), 4.52 (1.98)) and
drove at least 5,000 km per year. All participants were in
good health and reported no prior problems with drug or
alcohol abuse. Participation was voluntary and participants
received a monetary bonus.
Study design
The study was conducted according to a double-blind,
placebo-controlled, four-way cross-over design with treat-
ment orders counterbalanced. Participants were presented
with alcoholic drinks leading up to a BAC of 0.3‰, 0.5‰
or 0.8‰ and a placebo which looked and smelled like an
alcoholic beverage but contained no alcohol.
Procedure
The participants were instructed to abstain from alcohol in
the 24 h prior to the experiment and to refrain from
caffeinated beverages on the morning of the experiment.
They were then tested during five separate testing days.
Each test day started between 1 p.m. and 3 p.m. The first
testing day started with a screening of the participants by
questioning them about their lifestyle in relation to alcohol
and drugs using the Drug Abuse Screening Test-10
(Skinner 1982). After this screening the participants were
trained in the simulator for 30 min. In this training the
participants practised all of the driving scenarios in a full
dress rehearsal and were screened for simulator sickness.
On the other four testing days, participants were given
beverages containing vodka (40%) filled up with orange
juice until the intended BAC was reached (as measured by
a Dräger Alcotest® 7410 Plus breathalyzer) or only orange
juice with a spray of alcohol on top as a placebo. The
amount of administered alcohol was dependent on the
weight, height and gender of the participant and was
calculated using the Widmark formula (Widmark 1932).
The driving test was then conducted 20 min post-alcohol
intake and took approximately 50 min.
In order to keep the participant at a constant alcohol
level, the test was paused every 20 min to do a breath
analysis and administer extra alcohol when necessary. The
tests differed in the order of occurrence in different sessions
to prevent the participants from anticipating the critical
moments during the scenarios. After the driving task, the
participants were asked to fill in questionnaires and had to
wait in waiting room until they were able to return home
safely. The participants were only allowed to leave when
their BAC was below 0.1‰. The study was approved by
the ethical committee of the Department of Psychology at
the University of Groningen.
Apparatus
Participants were required to complete test rides in a
(fixed-base) driving simulator consisting of a mock-up
car with original controls (three pedals, clutch, steering
wheel, safety belt, indicator and hand brake) linked to a
dedicated graphics computer, registering driver behav-
iour while the road environment and dynamic traffic are
computed at 30 Hz+. Participants had a 180º view of
the road environment (see Fig. 1. for an illustration).
Other vehicles in the simulated world interact with each
other and the simulator car autonomously, and behave
according to hierarchically structured decision rules that
are based on human driving behaviour (Van Wolffelaar
and Van Winsum 1992).
Fig. 1 Illustration of the driving simulator
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A virtual world, including relevant scenarios for testing,
the effects of alcohol and drugs was developed for these
studies; see Veldstra et al. (2009), for a detailed overview.
The virtual environment consisted of several road types:
urban (6.5 km), rural (22.6 km) and motorway (9.8 km).
Average traffic densities were used on all of these road
types.
Driving tasks assessing automated driving performance
Speed management Speed was assessed on all road types.
Participants under the influence of alcohol might lower
their speed to compensate for sedating effects. On the other
hand, stimulating drugs such as MDMA might make the
participant want to speed up because hazard perception is
decreased (see also Brookhuis et al. 2004). Another
compensating mechanism in speed management is (delib-
erately) varying speed. In the case of severe sedation, a
participant might temporarily increase speed to increase
feelings of arousal, indicated by an increase in the standard
deviation of speed (Brookhuis 1998). Therefore, besides
average speed, the SDSP was assessed as well.
Road tracking task On two rural roads of approximately
10 km (posted speed 100 km/h) road tracking was
monitored. The road tracking task is designed to measure
involuntary (unconscious) response errors, or tracking
errors, calculated as the SDLP (O’Hanlon et al. 1982).
Driving tasks assessing complex driving performance
Car following Response to other traffic participants was
assessed using a car following test on a rural road
(Brookhuis et al. 1994). In this scenario the participant
was instructed to follow a lead car at a short but safe
distance. The lead car was programmed to change speed
between 60 and 80 km/h and to accelerate and decelerate
within a randomly varied frequency of between 0.025 and
0.05 Hz (20 and 40 s.). The participants’ reactions to these
speed changes were measured by assessing the coherence,
the gain and most importantly, the delay in their responses.
The coherence is the extent to which the patterns of speed
changes of the lead- and following car correspond. So, if
the participant is not following speed changes of the lead
car properly, the coherence would be low. However, if the
participant is following as instructed coherence would be
high. After coherence is established, the style of following
can also be analysed. This is done by assessing the gain and
the delay. The gain is a measurement of the type of speed
reaction the participants had to the speed changes of the
lead car and is returned as an amplification factor between
the speed signals of the lead- and follow car. When there is
an overreaction, the gain is larger than one, while at an
underreaction, the gain is smaller than one. The delay
(technically, phase shift between the two speed signals) is
the response time of the participant to the speed changes of
the lead car (see Brookhuis et al. 1994; De Waard and
Brookhuis 2000).
Gap acceptance The gap acceptance task was used to asses
risk taking in traffic (Adams 1995). In this task, participants
drove on a two lane urban road with a posted speed limit of
50 km/h and had to turn left at a y-junction through a
stream of oncoming traffic that had the right of way. The
time between each of the cars in this stream increased every
1 s, ranging from 1 to 12 s. In this task the driver had to
weigh the waiting time versus the risk of causing an
accident and come to a decision to either choose a small
risky gap, with a short waiting time or a larger, safer gap
with a longer waiting time. The parameters included to
assess the drivers risk taking were: the size of the chosen
gap in seconds and the distance to the car approaching the
driver while traversing the crossing. Accordingly, lower gap
time (in seconds) and a smaller distance to the approaching
car entails riskier behaviour.
Running red lights Analyses of driver records of patients
that admitted substance abuse showed that drug users had
significantly more traffic violations than a non-drug control
group (MacDonald et al. 2004). Therefore, the violation of
traffic regulations was assessed by a traffic light scenario
developed by De Waard et al. (1999). In this scenario the
participant approached a green traffic light that turned
amber just 2 s before the participant would be passing the
light (posted speed 50 km/h). If participants kept the same
speed they would drive through red, if they sped up they
would most likely drive through amber and if they wanted
to stop they had to brake firmly. The choice of the
participant was determined by assessing the colour of the
traffic light at the moment of crossing.
Car pulling out of a car park Alcohol intoxication and
sedation by (medicinal) drugs has been associated with
significant deterioration in attention and reaction time
(Kelly et al. 2004). A scenario used to measure the driver’s
reaction to unexpected events was a scenario in which a car
pulled out of a car park while driving in an urban area
(posted speed 50 km/h). The dependent measure was the
minimal time to collision.
Crashes Even though crashes tend to occur more frequently
in a driving simulator than in real traffic, it is still an
important indicator of driving safely. Having a crash is
the ultimate outcome of an unsafe act (Brookhuis et al.
2004). Therefore, the total number of crashes during the
entire ride was assessed.
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Subjective measures
Karolinska sleepiness scale A modified version of the
Karolinska Sleeping Scale (KSS; Reyner and Horne
1998) was used to assess the participants’ own feeling of
alertness before and after driving. Scores ranged from 1
(‘extremely alert’) to 9 (‘Sleepy, I have to fight not to fall
asleep’).
Rating scale mental effort The Rating Scale Mental Effort
(RSME; Zijlstra 1993) was used to assess whether there
was a difference in the mental effort participants had to
invest during the driving session for the different alcohol
conditions.
Driving quality scale Using the Driving Quality Scale
developed by Brookhuis et al. (1985), the participant had
to judge his or/her own performance. Driving quality was
rated by driver on a 10-cm visual analogue scale (0=poor;
10=excellent).
Data analysis
All statistical analyses were conducted by means of SPSS 16
for Windows. Normally distributed data were subjected to a
general linear model univariate repeated measures analysis
with alcohol level (four levels) as main within-subjects factor.
If the Mauchly’s test indicated that the assumption of
sphericity was violated, the degrees of freedomwere corrected
using the Greenhouse–Geisser correction. On the non-
normally distributed data, Friedman’s tests were performed
and contrasts were explored with the Wilcoxon exact test.
Dichotomous data were subjected to a Cochran’s test. Missing
values were corrected by replacing them with the mean of the
participant over all conditions (i.e. ipsative mean imputation;
Shafer and Graham 2002). This technique was chosen to
preserve the data. Replacement of missing values with
individual means was chosen over replacement with overall




The average alcohol levels in the three alcohol administration
conditions as measured by breath analyses were: 0.28‰
(SD=0.05), 0.49‰ (SD=0.08) and 0.80‰ (SD=0.10).
Automated driving performance
Speed management Average (+SE) performance scores and
p values for all driving tasks are displayed in Table 1. A
main within-subjects effect of alcohol level on speed was
revealed in the urban driving setting (F (2.29)=3.44, p<
0.05). The average speed was not above the posted speed
but participants tended to drive faster when their alcohol
level was above 0.5‰ as compared to placebo (on average
1.3 km/h (SE=0.58) faster (F (1)=5.37, p<0.05) when
BAC was 0.5‰ and on average 1.47 km/h (SE=0.76) faster
(F (1)=3.8, p=0.068) when BAC was 0.8‰). There was no
effect of alcohol level on speed when driving on the rural
road and motorway. Also, there was no effect of alcohol on
SDSP for any of the road types.
Road tracking As expected, there was a main within-subjects
effect of alcohol level on SDLP (F (2.08)=5.68, p<0.05). As
compared to the placebo, SDLP was decreased for
0.3‰ (−2.0 cm (F (1)=12.07, p<0.05)), 0.5‰ (−2.1 cm
(F (1)=4.15, p<0.05)) and 0.8‰ alcohol (4.1 cm
(F (1)=10.12, p<0.05)).
When comparing the different alcohol levels to each
other, contrast analyses revealed that the difference between
the SDLP with alcohol levels 0.3‰ and 0.5‰ was not
significant (F (1.0)=0.190, n.s.). However, the SDLP
difference between a 0.5‰ and 0.8‰ alcohol level was
significant (F (1.0)=5.165, p<0.05).
Complex driving performance
There was no within-subjects effect of alcohol level on
running red lights, reaction to the car pulling out of a car
park or the number of crashes (see Table 1).
Car following There was no main within-subject’s effect of
alcohol level on any of the car following measures. Overall
the coherence was high (average, 0.88 (SE, 0.014)),
indicating that participants were accurate in their speed
adaptations as reaction to the speed changes of the lead car;
this means that they were following the lead car as
instructed.
Gap acceptance There was no significant main effect of
alcohol level on gap times. When looking at the participants
distance to the approaching car, at the moment of crossing
the junction, it seems that participants generally accepted a
smaller distance when alcohol level was higher; however,
this effect was non-significant (F (2.81)=0.36, p<0.094) at
the p=0.05 level.
Subjective measures
Karolinska sleeping scale There was an overall effect for
time on task on the KSS (pre vs. post driving; F (1)=19.39,
p=0.001), with participants rating themselves as more
sleepy post driving. There was, however, no alcohol effect.
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Although the time on task effect appeared to increased with
alcohol level, the interaction effect of alcohol and time was
not significant (F (2.78)=2.56, p=0.07) at the p=0.05 level.
Rating scale mental effort There was an overall effect of
alcohol on ratings of mental effort (F (2.35)=4.07, p<
0.05). Participants rated their invested effort as higher in the
alcohol conditions as compared to the placebo condition.
Contrast tests revealed that this difference was significant
for the 0.5‰ alcohol condition (F (1)=12.04, p<0.05) and
the 0.8‰ alcohol condition (F (1)=4.76, p<0.05).
Driving quality scale There was no effect of alcohol on the
subjective assessment of driving performance. Participants
rated their performance to be slightly worse than normal in
all conditions.
Treatment evaluation More than half of the participants
guessed the amount of alcohol they had received correctly
(between 56% and 71%). The highest rate of correct
guesses was in the 0.8‰ alcohol condition (71%).
Binomial tests were applied to measure whether the
proportion of participants guessing the condition they were
in correct significantly differed from chance level (25%).
However, tests revealed no significant difference for any of
the alcohol conditions.
Discussion and conclusions
The results of the alcohol study indicate that alcohol mainly
influenced automated driving performance such as speed
control and weaving (SDLP). Speed on urban roads
increased when BAC was above 0.5‰. However, this
increase was small and did not exceed the posted speed.
SDLP increased as a function of BAC, indicating that
participants were weaving increasingly more as they were
under the influence of higher alcohol levels, comparable to
the well-known Borkenstein curve (Borkenstein et al. 1964)
and as also reported by Louwerens et al. (1987).
Car following was performed adequately as reflected in a
high coherence values; however, we found no effects of
alcohol on any of the car following measures. Previous
research on the influence of alcohol on car following
measures has been ambiguous. For example, De Waard and
Brookhuis (1991) reported a 19% increase in delay under
the influence of an alcohol level of 0.46‰, but no effect on
Table 1 Average (SE) of the driving tasks for all treatment conditions in study 1
Driving task Placebo Alcohol 0.3‰ Alcohol 0.5‰ Alcohol 0.8‰ Main within subjects effect
Road tracking
SDLP (cm) 15.77 (0.01) 17.71 (0.01) 17.88 (0.01) 19.88 (0.01) F (2.29)=3.44, p<0.05
Speed (km/h) 100.5 (2.6) 95.5 (2.4) 100.3 (1.8) 99.4 (2.2) χ2 (3)=5.26, n.s
SD speed (km/h) 1.6 (0.3) 1.8 (0.3) 1.6 (0.3) 2.4 (0.5) χ2 (3)=6.0, n.s
Car following
Coherence 0.89 (0.02) 0.90 (0.01) 0.88 (0.02) 0.87 (0.03) χ2 (3)=1.0, n.s
Gain 0.84 (0.3) 0.87 (0.3) 0.82 (0.3) 0.78 (0.2) χ2 (3)=2.87, n.s
Delay 3.49 (0.3) 3.35 (0.3) 3.67 (0.3) 3.31 (0.2) χ2 (3)=2.2, n.s
Motorway driving
Speed (km/h) 105.96 (3.9) 108.7 (3.7) 111.9 (3.9) 107.3 (5.4) χ2 (3)=1.87, n.s
Sd speed (km/h) 2.7 (0.2) 2.7 (0.3) 2.5 (0.2) 2.8 (0.3) F (2.56)=0.46, n.s
Urban Driving
Speed (km/h) 35.9 (0.6) 35.9 (0.6) 37.3 (0.7) 37.4 (0.6) F (2.29)=3.44, p<0.05
Sd speed (km/h) 17.5 (0.3) 17.5 (0.3) 17.6 (0.4) 17.5 (0.5) F (2.84)=0.09, n.s
Gap acceptance
Gap time (s) 5.7 (0.3) 5.7 (0.3) 5.4 (0.3) 5.5 (0.3) χ2 (3)=0,913, n.s
Distance to car (m) 53.3 (5.1) 48.5 (5.1) 46.7 (4.11) 41.0 (6.7) F (2.81)=0.36, n.s
Car pulling out of parking
TTC 1.61 (0.15) 1.26 (0.18) 1.58 (0.33) 1.42 (0.11) χ2 (3)=1.255, n.s
Running red light χ2 (3)=5.53, n.s
(% running red) 23.5 11.8 29.4 35.3
(% running amber) 0 0 0 0 –
No. of crashes 3 0 2 1 –
Significance indicated by p value
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gain, whereas Kuypers et al. (2006) reported no significant
effect of alcohol (at 0.37‰) on delay or gain.
The aim of study 1 was to serve as a reference for driving
under the influence of MDMA and combined MDMA and
alcohol in automated but also in more complex driving tasks.
However, the majority of the scenarios in which more
complex driving performance was assessed showed no
significant differences from the placebo and could therefore
not be used as references for the second study. For only one
scenario, an effect of alcohol on performance was found,
namely the gap acceptance scenario.
Since drug-affected drivers have demonstrated reduced
perceptions of risk (Brookhuis et al. 2004), one might have
expected to find a smaller gap time when BAC was higher.
However, participants selected approximately the same gap
irrespective of their BAC. Only the average distance of the
participants to the approaching car at the moment of
crossing was affected by alcohol, in that the average
distance was smaller when BAC was higher. Since the
perceptual motor capacities necessary for crossing the
junction tend to be affected by alcohol, both in speed and
coordination (Tarter et al. 1971), it probably took the
participants a bit longer to initiate a reaction. One could
argue that the participants were taking a greater risk by
accepting the same gap while ignoring initiation capabili-
ties. It would have been safer to wait for a larger gap, since
it would take more time to cross.
As stated, the effects of alcohol were mainly found on
automated driving performance and were not found in the
scenarios where more complex driving behaviour was
measured. This might be due to the dynamic nature of these
kinds of tasks. Since the scenarios measuring complex driving
performance are so dynamic, they allow for different
strategies to compensate for intoxicating effects. For example,
where one participant might have reduced speed to have an
increased reaction time to unexpected events, another might
have adopted an alternative strategy in which altering speed
was not necessary. For automated driving tasks, these
compensatory strategies are limited and may therefore be
more sensitive to drug-induced effects. Fairclough and
Graham (1999) hypothesised that compensatory responses
are triggered by the awareness and subjective discomfort of
reduced performance efficacy. Although the current study
was double blind, the majority of the participants still
guessed the alcohol condition they were in correctly and
may perhaps have responded by compensating for the
impairing effects. One way in which they did this was by
investing more mental effort, since scores on the RSME
increased for the higher alcohol levels. This might also
explain why participants felt they had not driven any worse
under the influence of any of the alcohol conditions as
compared to the placebo when asked to rate their own
driving performance.
In conclusion, the effects of alcohol were mainly found
on automated driving performance such as weaving and
speed control. Therefore, these are the main parameters that
will serve as references for the second study on the
influence of MDMA and alcohol on driving performance.
Study 2: the effects of MDMA and alcohol
Methods and materials
Participants
Participants were recruited by flyers distributed at the
University of Groningen. In the beginning 20 volunteers
participated in this study. However, one participant did
not comply with the rules of participation and was
therefore discarded from further analyses. This partici-
pant tested positive for MDMA in the placebo condition
even though he had tested negative in the urine drug
screen as was conducted at the start of every testing
day. This became apparent during the post hoc pharma-
cological analyses. Therefore, 19 healthy volunteers (ten
males, nine females) aged between 21 and 40 years
(mean (SD), 30.8 (5.65)) were used for further analyses.
They were all experienced drivers who had held their
driving licence between 3 to 20 years (mean (SD), 8.8
(5.7)) and had all used MDMA before participating in
the study (lifetime use varied between 10 and 100 pills).
Moreover, they had experience with alcohol use but
were not abusers (participants on average drank 7.8
(SD=5.8) alcoholic beverages per week).
Participants were medically examined by a medical
supervisor. Vital signs were checked and standard blood
chemistry was examined. Inclusion criteria were: experi-
ence with the use of MDMA (at least five times in the past
12 months); experience with the use of alcohol (2–20
consumptions a week); free from psychotropic medication;
good physical health as determined by examination and
laboratory analysis; good medical, endocrine and neurolog-
ical condition; normal weight, body mass index between 18
and 28 kg/m2; a valid driving licence (minimum 3 years);
driving experience with a minimum of 5,000 km per year
and written informed consent. Exclusion criteria were: a
history of drug abuse or addiction as determined by
examination; excessive drinking (>20 alcoholic consump-
tions a week); current or history of psychiatric disorder;
history of malignant hyperthermia/serotonin syndrome;
cardiovascular abnormalities as assessed by standard
ECG; hypertension (diastolic >100; systolic >170); preg-
nancy, lactation or wishing to become pregnant during the
period of the study; participation in any clinical trial
including blood sampling and/or administration of substan-
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ces up to 6 weeks before the study and susceptibility to
simulator sickness (participants were pre-tested).
This study was conducted according to the code of ethics
on human experimentation established by the declaration of
Helsinki (latest revision, Seoul 2008) and in accordance
with the Medical Research Involving Human Subjects Act
(WMO). Approval for the studies was obtained from the
Medical Ethics Committee of the University Medical
Centre of Groningen and the Dutch Central Committee on
Research Human Subjects (CCMO). A permit for obtain-
ing, storing and administering MDMA was obtained from
the Dutch drug enforcement administration.
Design and treatment
The study design was a double-blind, placebo-controlled,
four-way crossover design with treatment orders counter-
balanced according to a Latin square. On the testing days, the
participants randomly received a single dose of 100 mg
MDMA, or placebo, and a single dose of alcohol (aiming at
BAC 0.5‰) or placebo. The placebos, alcohol and MDMA
where administered orally. Alcohol was administered accord-
ing to the same procedure as in the alcohol reference study
(study 1) and MDMA and placebo–MDMA were adminis-
tered in a capsule. MDMA (or placebo) was obtained from
Duchefa Pharma B.V. Haarlem, Nl, the Netherlands and
encapsulated according to EU Good Manufacturing Practice
by Basic Pharma Geleen, N1, the Netherlands.
Procedure
After there was no medical objection for participation,
participants were invited to come in for a training day to
check for simulator sickness and to practise all of the driving
scenarios in a full dress rehearsal. After the training day,
participants visited the facilities four additional times (1 day
for each condition), with a washout period of 1 week in
between. Participants were asked to refrain from any drugs
starting 1 week before the screening and during the whole
study period. Drug screens in urine and alcohol screened in
breath were conducted before the start of every testing day.
Female participants were also screened for pregnancy.
Participants were allowed to take part on the testing day only
if they had passed these screenings. Furthermore, participants
were asked to refrain from alcohol and on the day prior to the
testing day and from caffeinated beverages on the testing day
itself. Participants were compensated for their participation by
means of a monetary reward.
Pharmacokinetic assessment
Two blood samples (10 ml) were taken 1.5 h post-drug.
One sample was centrifuged after collection for 15 min at
ca. 2,000 rpm at ca. 4°C for the extraction of serum. Saliva
was collected every hour until 7 h post-drug-intake with a
StatSure’s Saliva Sampler (®). After collection all samples
were stored at −20°C until further analyses. Furthermore,
dried bloodspots were collected by finger prick for a special
drug assessment kit provided by the University of Heidelberg
in order to investigate a new less invasive way of
testing for drugs in blood (Jantos et al. 2011).
Driving tasks
Driving tests were conducted between 1.5 and 3.5 h post
MDMA (30 min after the first alcohol administration
10 min after subsequent administrations). Alcohol level
was kept constant during all parts of the drive. The same
measures employed in study 1 were also used in study 2.
Subjective measures
The same subjective measures employed in study 1 were
also used in study 2. In addition, we asked participants in
the introduction session how they thought the different drug
conditions would influence their driving performance on a
scale ranging from 0 (worse) to 12 (better). We then asked
them again after every driving session, to see whether they
thought that the drug they had had may have influenced
their driving performance.
Data analysis
Treatment effects were handled in the same way as in
study 1. After the assessment of treatment effects, a so
called equivalence test was conducted on measures in
which the treatment effect in the alcohol reference study
was significant. In this test the equivalence of drug
effects based on the difference to the placebo were
compared to the criterion levels as established in the
alcohol reference study. Equivalence was tested by
assessing if the pre-established criterion levels fell
within the 95% confidence interval of the drug effects.
If this was so, then the drug effect was considered to be
clinically relevant (Mascha and Sessler 2011). Further-
more, concentration-effect relations were determined by
regressing concentrations of MDMA in blood and saliva
for both the MDMA- and MDMA co-administered with
alcohol condition to behavioural measures.
Results
Pharmacokinetics
BAC levels were 0.48‰ (SD=0.11) for the alcohol-alone
condition and 0.50‰ (SD=0.11) for the alcohol–MDMA
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condition. MDMA and MDA concentrations in blood
(serum, whole blood and dry bloodspots) and oral fluid
were comparable between treatments (see Table 2 and for
further analyses see also Jantos et al. 2011). As can be seen
in Fig. 2, MDMA in saliva peaked 2 h after intake and
decreased in the 2 h following. Hereafter, the level was
relatively stable for the remaining hours that were mea-
sured. Measures of MDMA concentration in dried blood
and whole blood correlated weakly with peak concentra-
tions in oral fluid (r=0.324, p=0.07 for both dried blood
spots and whole blood). There was no correlation between
serum and oral fluid MDMA concentrations. This is in line
with Samyn et al. (2002).
Automated driving performance
Mean (SE) performance scores for all driving tasks and p
values for main treatment effects are displayed in Table 3
Speed management Participants kept to the posted speed on
all road types. However, on the rural roads where they
could drive more freely, the participants showed a main
effect of treatment on speed (χ2 (3)=8.21, p <0.05). Simple
contrasts analyses revealed that this difference stems mainly
from a decrease in speed in the MDMA condition as
compared to the placebo condition (average Δ (SE),
0.95 km/h (0.36); Z=2.66, p<0.05). Moreover, there was
a main effect of treatment on the SDSP when participants
were driving on the rural road (χ2 (3)=10.33, p<0.02). The
SDSP was higher when participants were driving under the
influence of alcohol 0.5‰ as compared to the placebo
(average Δ (SE), 0.41 km/h (0.30); Z=2.05, p<0.05).
Furthermore, there was an interaction effect of alcohol
(0.5‰ and placebo) and MDMA (100 mg and placebo) on
SDSP. The SDSP was significantly lower when driving
under the influence of MDMA than when under the
influence of alcohol (average Δ (SE), 0.55 km/h (0.24);
Z=2.61, p<0.05).
Road tracking As expected, there was a main within-subjects
effect of treatment on weaving, measured as the SDLP (F
(2.72)=6.16, p<0.005). As can be seen in Fig. 3, compared
to placebo, SDLP increased 1.11 cm under the influence of
combined alcohol and MDMA administration. However, this
difference was not significant (F (1)=1.12, n.s). Moreover,
SDLP increased 2.42 cm under the influence of alcohol
(F (1)=5.3, p<0.05) and decreased 1.84 cm under the
influence of MDMA (F (1)=5.3, p<0.05). This interaction
effect of Δ SDLP when treated with BAC 0.5‰ and Δ SDLP
when treated with MDMAwas also significant (F (1)=15.17,
p<0.001). Although Δ SDLP when treated with MDMA
alone was significantly lower than SDLP under the influence
of BAC 0.5‰ for the combined treatment of MDMA and
alcohol, it was not (F (1)=1.61, n.s). When comparing
average Δ SDLP under the influence of BAC 0.5‰ in the
current study with the first study, no significant difference
was found (t (34)=0.204, n.s.). Therefore, equivalence could
be tested. Equivalence testing demonstrated that increments
in SDLP when treated with combined alcohol 0.5‰ and
MDMA were equivalent to the pre-established margin at
BAC 0.5‰ and even 0.8‰. When looking at the 95%
confidence interval for the Δ SDLP under the influence of
combined alcohol and MDMA (see Fig. 3), one can see that
the upper bound clearly exceeds the pre-established margins
of both BAC 0.5‰ (2.1 cm) and BAC 0.8‰ (4.1 cm). This
indicates that within the range of possible means an average
SDLP impairment that is larger than impairment under BAC
0.5‰ or even BAC 0.8‰ could be found. T tests comparing
the two criterion levels to Δ SDLP in the combined treatment
condition confirm this assertion since they showed no
significant difference when compared with BAC 0.5‰
(t (34)=0.68, n.s) and BAC 0.8‰ (t (34)=−1.83, n.s.).
However, the lower bound of the confidence interval spreads
over the null line as well; indicating that a subset of
individuals may show no impairment or even an average
improvement (i.e. decrease) in SDLP as compared to the
placebo.
Analyses reveal that there was an effect of time on task
for SDLP (F (1.93)=12.05, p<0.001). Overall SDLP
increased over time (see Fig. 4). Furthermore, there was a
slight effect for the treatment by time interaction (F (6)=
2.45, p=0.088). As can be seen in Fig. 4, SDLP increases
sturdily with time in all conditions except in the MDMA
condition in which it only increase lightly. Regression of
the SDLP differences to placebo in both the MDMA- and
MDMA co-administered with alcohol condition on drug
concentrations in saliva and serum showed a general lack of
association (see Fig. 5).
Table 2 Average (SD) concen-
tration MDMA and MDA in





MDMA MDMA and alcohol MDA MDA and alcohol
Serum 150.72 (144.95) 135.45 (131.38) 3.13 (3.66) 3.21 (3.10)
Whole blood 170.41 (160.22) 159.25 (148.68) 6.69 (7.79) 5.67 (6.57)
DBS 173.70 (164.22) 162.50 (152.76) 6.52 (7.74) 6.28 (6.76)
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Complex driving performance
There was no within-subjects effect of alcohol level on gap
acceptance, running red lights, the car pulling out of a car
park scenario or the number of crashes.
Car following There was no main within-subject’s effect of
treatment on any of the car following measures. Overall the
coherence was lower than in study 1 (average (SE), 0.77
(0.03)) but even when correcting for the low coherence by
only analysing participants with a coherence of above 0.75;
there was no main effect of drug conditions on any of the
car following measures.
Subjective measures
Treatment evaluation At the end of every session,
participants were asked in which condition they thought
Table 3 Average (SE) of the driving tasks for all treatment conditions in study 2
Driving task Placebo Alcohol MDMA MDMA with alcohol Main within- subjects effect
Road tracking
SDLP (cm) 21 (1.2) 24 (1.3) 19 (1.0) 22 (1.3) F (2.72) =6.16, p<0.005
Speed (km/h) 105.8 (2.2) 105.8 (2.8) 102.24 (1.4) 104.1 (2.0) χ2 (3)=8.21, p <0.05
SD speed (km/h) 3.0 (0.6) 4.5 (0.9) 2.5 (0.3) 3.7 (0.6) χ2 (3)=10.33, p<0.02
Car following
Coherence 0.74 (0.06) 0.81 (0.03) 0.75 (0.05) 0.79 (0.03) χ2 (3)=1.80, n.s.
Gain 5.2 (0.6) 4.8 (0.5) 5.5 (0.6) 4.6 (0.4) χ2 (3)=1.86, n.s.
Delay 0.73 (0.05) 0.77 (0.06) 0.75 (0.05) 0.79 (0.05) F (2.52)=0.59, n.s.
Motorway driving
Speed (km/h) 121.7 (3.2) 119.8 (4.0) 118.6 (2.5) 121.5 (3.8) χ2 (3)=4.45, n.s.
Sd speed (km/h) 6.3 (0.8) 6.6 (0.9) 6.3 (1.0) 7.2 (1.2) F (2.16)=0.23, n.s.
Urban driving
Speed (km/h) 46.7 (0.9) 47.0 (1.0) 48.2 (0.8) 47.6 (1.3) F (2.77)=0.94, n.s.
Sd speed (km/h) 5.6 (0.3) 5.8 (0.2) 5.1 (0.4) 6.1 (0.4) F (2.66)=2.75, n.s.
Gap acceptance
Gap time (s) 4.0 (0.2) 4.1 (0.2) 4.1 (0.2) 4.0 (0.2) F (2.52)=0.25, n.s.
Distance to car (m) 30.6 (1.9) 32.2 (2.1) 32.3 (1.9) 32.9 (2.3) F (2.51)=0.63, n.s.
Car pulling out of parking
TTC 1.39 (0.09) 1.30 (0.09) 1.27 (0.11) 1.31 (0.09) χ2 (3)=3.26, n.s.
Running red light χ2 (3)=5.56, n.s.
(% running red) 63.2 52.6 68.4 68.4 –
(% running amber) 5.3 0 0 10.5 –
No. of crashes 1 2 2 3 –
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they were in. The majority of participants guessed
correctly (between 68% and 89%). Binomial tests were
applied to measure whether the proportion of partic-
ipants guessing the condition they were in correct
significantly differed from chance level (25%). For all
conditions except the MDMA co-administered with
alcohol condition, this was the case.
Driving quality assessment When asking participants in the
introduction session how they thought the different drug
treatments would influence their driving performance,
participants predicted their performance to be worse than
normal. Furthermore, participants thought their driving
would deteriorate more when treated with combined
alcohol and MDMA as compared when they were treated
with alcohol only (Z=2.60, p<0.009) or only with MDMA
(Z=2.42, p<0.05). After testing the participants were asked
if the treatment they thought that they had had may have
influenced their driving performance. Overall, participants
thought that the drug treatment that they had received
would still make them drive a little worse than normal.
However, this time they expected that the influence on their
driving performance did not differ between treatments.
Furthermore, we compared the pre-driving test subjec-
tive ratings with post-driving test ratings of participants
who had guessed the treatment they had received
correctly. Participants rated the influence of the treat-
ment on their performance worse in the pre- as
compared to the post-driving test. This difference was
significant for both the MDMA (Z=2.6, p<0.007) and
the combined MDMA/alcohol condition (Z=2.52, p<
0.008), but not for the alcohol condition (Z=2.39, p=n.s).
There was, however, no effect of treatment on self rated
driving quality (χ2 (4)=1.68, n.s.).
Rating scale mental effort There was no effect of treatment
on the RSME (χ2 (4)=0.84, n.s).
Karolinska sleepiness scale The average ratings of alertness
as measured by the KSS pre-driving test were equal over all
conditions. However, participants gave higher average ratings
post- driving test as compared to pre-driving test (χ2 (7)=
32.81. p<0.001), indicating that they rated themselves as less
alert after the driving tests. Analyses of contrasts reveal that
this difference was significant for the placebo (Z=2.48, p<
0.05), alcohol (Z=3.02, p<0.001) and combined alcohol–
MDMA (Z=2.16, p<0.05) conditions but not for the
MDMA only condition (Z=1.04, n.s).
Discussion and conclusions
The effect of 0.5‰ alcohol on weaving in this study was
very similar to the effect of alcohol 0.5‰ found in the
alcohol reference study. Moreover, an increase in SDLP of
about 2.4 cm is almost identical to findings in other
simulator- (Thompson et al. 2010) and on-road-driving
studies (Kuypers et al. 2006; Louwerens et al. 1987;
Ramaekers et al. 2006). As reported before in other studies
(Ramaekers and Kuypers 2006; Ramaekers et al. 2006),
SDLP was positively affected by MDMA (alone). Al-
though, the moderating effect of MDMA on alcohol as
found by Kuypers et al. (2006) failed to reach significance
in this study. Equivalence testing demonstrated, though,
that combined use could lead to impairment that is
equivalent to BAC 0.5‰ or even BAC 0.8‰ since the
upper limit of 95% confidence interval associated with the
mean SDLP change in the combined treatment condition
clearly exceeded the pre-established margin of both alcohol
levels. However, the lower bound of the confidence interval
spreads over the null line as well, indicating that a subset of
participants may not be impaired or even slightly improved
with respect to SDLP performance as compared to the
placebo condition. Furthermore, this illustrates the large
variance found in performance. Apparently, participants
Fig. 3 SDLP, average difference to placebo and 95% CI per condition
for road tracking and equivalence to alcohol–placebo difference at
levels 0.5‰ and 0.8‰ as established in study 1
Fig. 4 Average SDLP and 95% CI per treatment condition as function
of part of the road tracking drive
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were differentially influenced by the different drug con-
ditions. The lack of association between drug concentra-
tions and performance confirms this assertion.
When looking at the time on task effects of the
tested substances on weaving (SDLP), it was apparent
that SDLP increased sturdily over time for all treatment
conditions but only slightly for the MDMA-only
condition. This indicates that participants might keep
up their vigilance for a longer period of time because of
the stimulating effects of MDMA. However, this
stimulation did not appear to be not large enough to
uphold when MDMA was co-administered with alcohol
since the pattern of weaving increase observed was the
same in the co-administration condition as in the
placebo and alcohol condition. This is in line with the
alertness ratings of participants before and after driving,
in that the participants indicated they felt less alert after
driving as compared with before driving in all treatment
conditions except in the MDMA condition.
A behavioural compensating mechanism to keep up
vigilance is (deliberately) varying speed. In the case of
sedation, as would be experienced in the alcohol condition,
a participant might temporarily increase speed to increase
feelings of arousal as can be seen in an increase in the
standard deviation of speed (Brookhuis 1998). Although
this was not a strategy chosen by the group of participants
in the first alcohol reference study, in the second, MDMA
study participants did tend to vary their speed more when
treated with alcohol only as compared to the placebo, but
only when driving on the rural road. This is the kind of road
type where one would expect such a behavioural compen-
sation, since it is a monotonous road with little other traffic
participants to consider. Furthermore, SDSP decreased
when under the influence of MDMA only which would
be expected since MDMA increases feelings of alertness
and vigilance (Kuypers et al. 2007) therefore diminishing
the need for behavioural compensation.
Another compensation mechanism for driving under the
influence of sedating drugs such as alcohol is lowering ones
speed. Furthermore, Brookhuis et al. (2004) reported an
increase in speed when participants were under the influence
of MDMA in urban areas and on the motorway. In the
Fig. 5 Regression lines for SDLP difference to placebo and MDMA concentrations in serum and saliva during driving tests when treated with
MDMA and MDMA co-administered with alcohol
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current study, however, participants kept to the posted speed
on all road types and in the MDMA condition even
decreased speed a bit more when driving on the rural road.
Car following remained unaffected under all treatment
conditions. Overall coherence was relatively low, indicating
that participants were following the lead car less well, which
may have disturbed the measurement of car following. This is
in line with Brookhuis et al. (2004), who also reported no
significant effects of drug conditions on car following.
As said, the aim of the study was to investigate more
complex driving behaviour as well and compare it to
driving under the influence of different levels of alcohol. In
the alcohol reference study, we found little to no effects of
alcohol on any of measures assessing complex driving
behaviour. Similarly, in the MDMA study, there were no
effects found of any of the treatment conditions on the
performance measures in these more complex scenarios.
One factor that might have contributed to variance in
performance was the variance of the MDMA concentra-
tions, as detected in saliva and, especially, in blood. It has
previously been postulated that individuals might geneti-
cally differ in their metabolism of the drug (e.i. slow
metabolizers versus rapid metabolizers). Individuals may
therefore have variable concentrations of the parent
compound and metabolites in blood after the same dose
was administered (De La Torre et al. 2004; Oesterheld et al.
2004). Although this might explain the high variance of the
MDMA in bodily fluids, it does not explain the lack of
association with behavioural results. In the alcohol study, it
was proposed that this might be due to variance in
compensation strategies which make it hard to come to
one conclusion about the average effects of treatments on
measures in the complex driving scenarios.
This idea is supported in this study when looking at the
large variances, especially in the multidrug condition. This
was coincidently also the condition in which most
participants’ guessed the treatment they had received
incorrectly. Anecdotally, some participants indicated not to
have noticed that they were administered alcohol in
addition to MDMA. If drivers are not aware of the
intoxicating effects of alcohol when driving under the
influence of MDMA, and therefore do not feel the
subjective discomfort of reduced performance efficacy,
they might not compensate accordingly.
Moreover, when comparing self assessment of driving
performance with the automated driving results, we could
conclude that in case of alcohol consumption the self
evaluation led to the wrong conclusions. In this condition
participants rated their performance before and after driving
under the influence as the same: that is, slightly worse than
normal. Since their driving was actually seriously deterio-
rated, this conclusion was a falsely positive assessment of
the situation. In the case of MDMA, the opposite was the
case. The driving performance of the MDMA users was
better than their self-assessment. Moreover, participants
predicted their driving behaviour to deteriorate most when
driving under the influenced of combined substances, but
after having driven under the influence of the combined
treatment condition performance was rated as the same to
all other treatment conditions. This dissociation between
subjective perceptions and objective performance impacts is
an additional important notion for traffic safety since it
might affect a driver’s judgement of whether or not it is safe
to drive. An intoxicated individual might decide to drive
because the feelings of alertness caused by MDMA cloud
the impairing effects of other drugs such as alcohol, thereby
implying a serious risk for traffic safety.
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